MedPath
HSA Approval

INTRALIPID INFUSION 20%

SIN05269P

INTRALIPID INFUSION 20%

INTRALIPID INFUSION 20%

December 15, 1990

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD
Licence HolderFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

INJECTION

**Infusion Bottle** **Posology and method of administration** The ability to eliminate INTRALIPID should govern the dosage and infusion rate. See below **Fat elimination**. **DOSAGE Intralipid 10%** 1g triglycerides corresponds to 10 ml INTRALIPID 10%. **_Adults._** The recommended maximum dosage is 3 g triglycerides/kg body weight/day. Within this upper limit, INTRALIPID can be given to contribute up to 70% of the energy requirements, also in patients with highly increased energy requirements. The infusion rate for INTRALIPID 10% should not exceed 500 ml in 5 hours. _**Neonates and infants.**_ The recommended dosage range in neonates and infants is 0.5–4 g triglycerides/kg bw/day. The rate of infusion should not exceed 0.17 g triglycerides/kg bw/hour (4 g in 24 hours). In prematures and low birthweight neonates, INTRALIPID should preferably be infused continuously over 24 hours. The initial dosage should be 0.5–1 g/kg bw/day followed by a successive increase by 0.5–1 g/kg bw/day up to 2g/kg bw/day. Only with close monitoring of serum triglyceride concentration, liver tests and oxygen saturation may the dosage be increased to 4 g/kg bw/day. The rates given are maximum rates and no attempt should be made to exceed these in order to compensate for missed doses. When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed. **DOSAGE Intralipid 20%** 1g triglycerides corresponds to 5 ml INTRALIPID 20%. **_Adults._** The recommended maximum dosage is 3 g triglycerides/kg body weight/day. Within this upper limit, INTRALIPID can be given to contribute up to 70% of the energy requirements, also in patients with highly increased energy requirements. The infusion rate for INTRALIPID 20% should not exceed 500 ml in 5 hours. _**Neonates and infants.**_ The recommended dosage range in neonates and infants is 0.5–4 g triglycerides/kg bw/day. The rate of infusion should not exceed 0.17 g triglycerides/kg bw/hour (4 g in 24 hours). In prematures and low birthweight neonates, INTRALIPID should preferably be infused continuously over 24 hours. The initial dosage should be 0.5–1 g/kg bw/day followed by a successive increase by 0.5–1 g/kg bw/day up to 2g/kg bw/day. Only with close monitoring of serum triglyceride concentration, liver tests and oxygen saturation may the dosage be increased to 4 g/kg bw/day. The rates given are maximum rates and no attempt should be made to exceed these in order to compensate for missed doses. When used in neonates and children below 2 years, the solution (in bottles and administration sets) should be protected from light exposure until administration is completed. _**Essential fatty acid deficiency**_ (EFAD). To prevent or correct essential fatty acid deficiency, 4 to 8% of the nonprotein energy should be supplied as INTRALIPID to provide sufficient amounts of linoleic and linolenic acid. When EFAD is associated with stress, the amount of INTRALIPID needed to correct the deficiency may be substantially increased. _**Administration.**_ INTRALIPID may be infused into the same central or peripheral vein as carbohydrates/amino acid solutions by means of a Y-connector near infusion site. INTRALIPID can also be given in a phthalate-free plastic bag as one part of an All in One admixture containing also carbohydrates, amino acids, electrolytes, vitamins and trace elements. The admixtures must be approved for physical stability according to Fresenius Kabi standards. **Fat Elimination** **_Adults._** The ability to eliminate fat should be closely monitored in patients with conditions mentioned in section “Special warnings and special precautions for use” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, and in patients given Intralipid for more than one week. This is done by collecting a blood sample after a fat-free clearance period of 5–6 hours. Blood cells are then separated from plasma by centrifugation. If the plasma is opalescent, the infusion should be postponed. The sensitivity of this method is such that hypertriglyceridaemia can pass undetected. Therefore, it is recommended that serum triglyceride concentrations should be measured in patients who are likely to have impaired fat tolerance. _**Neonates and infants.**_ The ability to eliminate fat should be tested regularly in neonates and infants. Measuring serum triglyceride levels is the only reliable method. **Excel Bag** **Posology and method of administration** The ability to eliminate INTRALIPID should govern the dosage and infusion rate. See below **Fat elimination**. **DOSAGE Intralipid 10%** 1g triglycerides corresponds to 10 ml INTRALIPID 10%. **_Adults._** The recommended maximum dosage is 3 g triglycerides/kg body weight/day. Within this upper limit, INTRALIPID can be given to contribute up to 70% of the energy requirements, also in patients with highly increased energy requirements. The infusion rate for INTRALIPID 10% should not exceed 500 ml in 5 hours. _**Neonates and infants.**_ The recommended dosage range in neonates and infants is 0.5–4 g triglycerides/kg bw/day. The rate of infusion should not exceed 0.17 g triglycerides/kg bw/hour (4 g in 24 hours). In prematures and low birthweight neonates, INTRALIPID should preferably be infused continuously over 24 hours. The initial dosage should be 0.5–1 g/kg bw/day followed by a successive increase by 0.5–1 g/kg bw/day up to 2g/kg bw/day. Only with close monitoring of serum triglyceride concentration, liver tests and oxygen saturation may the dosage be increased to 4 g/kg bw/day. The rates given are maximum rates and no attempt should be made to exceed these in order to compensate for missed doses. When used in neonates and children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed. **DOSAGE Intralipid 20%** 1g triglycerides corresponds to 5 ml INTRALIPID 20%. **_Adults._** The recommended maximum dosage is 3 g triglycerides/kg body weight/day. Within this upper limit, INTRALIPID can be given to contribute up to 70% of the energy requirements, also in patients with highly increased energy requirements. The infusion rate for INTRALIPID 20% should not exceed 500 ml in 5 hours. _**Neonates and infants.**_ The recommended dosage range in neonates and infants is 0.5–4 g triglycerides/kg bw/day. The rate of infusion should not exceed 0.17 g triglycerides/kg bw/hour (4 g in 24 hours). In prematures and low birthweight neonates, INTRALIPID should preferably be infused continuously over 24 hours. The initial dosage should be 0.5–1 g/kg bw/day followed by a successive increase by 0.5–1 g/kg bw/day up to 2g/kg bw/day. Only with close monitoring of serum triglyceride concentration, liver tests and oxygen saturation may the dosage be increased to 4 g/kg bw/day. The rates given are maximum rates and no attempt should be made to exceed these in order to compensate for missed doses. When used in neonates and children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed. _**Essential fatty acid deficiency**_ (EFAD). To prevent or correct essential fatty acid deficiency, 4 to 8% of the nonprotein energy should be supplied as INTRALIPID to provide sufficient amounts of linoleic and linolenic acid. When EFAD is associated with stress, the amount of INTRALIPID needed to correct the deficiency may be substantially increased. _**Administration.**_ INTRALIPID may be infused into the same central or peripheral vein as carbohydrates/amino acid solutions by means of a Y-connector near infusion site. INTRALIPID can also be given in a phthalate-free plastic bag as one part of an All in One admixture containing also carbohydrates, amino acids, electrolytes, vitamins and trace elements. The admixtures must be approved for physical stability according to Fresenius Kabi standards. **Fat Elimination** **_Adults._** The ability to eliminate fat should be closely monitored in patients with conditions mentioned in section “Special warnings and special precautions for use” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, and in patients given Intralipid for more than one week. This is done by collecting a blood sample after a fat-free clearance period of 5–6 hours. Blood cells are then separated from plasma by centrifugation. If the plasma is opalescent, the infusion should be postponed. The sensitivity of this method is such that hypertriglyceridaemia can pass undetected. Therefore, it is recommended that serum triglyceride concentrations should be measured in patients who are likely to have impaired fat tolerance. _**Neonates and infants.**_ The ability to eliminate fat should be tested regularly in neonates and infants. Measuring serum triglyceride levels is the only reliable method.

INTRAVENOUS

Medical Information

**Therapeutic Indications** INTRALIPID is indicated in patients needing intravenous nutrition to supply energy and essential fatty acids. INTRALIPID is also indicated in patients with essential fatty acid deficiency (EFAD) who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

**Contra-indications** INTRALIPID is contraindicated in patients with acute shock and those with severe disturbances in lipid metabolism such as pathologic hyperlipemia. INTRALIPID is also contraindicated in patients with severe liver insufficiency, hemophagocytotic syndrome, hypersensitivity to egg-, soya- or peanut protein or to any of the active substances or excipients. INTRALIPID also should not be used in patients with acute myocardial infarction until the condition has stabilized.

B05BA02

fat emulsions

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Fresenius Kabi SSPC

Fresenius Kabi AB

Active Ingredients

SOYABEAN OIL (FRACTIONATED)

200 mg/ml

Soybean oil

Documents

Package Inserts

Intralipid Infusion PI_in Excel Bag.pdf

Approved: September 24, 2020

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

INTRALIPID INFUSION 20% - HSA Approval | MedPath